The stock of Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) is a huge mover today! About 304,357 shares traded hands. Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) has declined 32.29% since April 4, 2016 and is downtrending. It has underperformed by 33.38% the S&P500.
The move comes after 5 months positive chart setup for the $124.41M company. It was reported on Nov, 4 by Barchart.com. We have $5.63 PT which if reached, will make NASDAQ:TTPH worth $82.11M more.
Analysts await Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) to report earnings on November, 7. They expect $-0.49 EPS, 0.00% or $0.00 from last year’s $-0.49 per share. After $-0.47 actual EPS reported by Tetraphase Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts 4.26% negative EPS growth.
Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) Ratings Coverage
Out of 11 analysts covering Tetraphase Pharmaceuticals (NASDAQ:TTPH), 1 rate it a “Buy”, 0 “Sell”, while 10 “Hold”. This means 9% are positive. Tetraphase Pharmaceuticals has been the topic of 15 analyst reports since August 6, 2015 according to StockzIntelligence Inc. As per Wednesday, September 9, the company rating was downgraded by Brean Capital. SunTrust downgraded the stock to “Neutral” rating in Wednesday, September 9 report. On Wednesday, September 9 the stock rating was downgraded by Robert W. Baird to “Neutral”. The firm earned “Neutral” rating on Wednesday, September 9 by Wedbush. On Thursday, November 19 the stock rating was upgraded by SunTrust to “Buy”. Brean Capital maintained the stock with “Buy” rating in Thursday, August 6 report. Nomura downgraded the shares of TTPH in a report on Wednesday, September 9 to “Neutral” rating. Stifel Nicolaus maintained the shares of TTPH in a report on Thursday, August 6 with “Buy” rating. The rating was downgraded by Cantor Fitzgerald to “Hold” on Wednesday, September 9. The firm has “Hold” rating by Stifel Nicolaus given on Wednesday, September 9.
According to Zacks Investment Research, “Tetraphase Pharmaceuticals, Inc. is a life science company engaged in developing and commercializing tetracycline based drugs to treat drug-resistant infectious diseases, inflammation, and cancer. Its principal products include eravacycline, an intravenous and oral antibiotic for the treatment of multi-drug resistant Gram-negative infections. The Company’s product under development includes eravacycline oral formulation, TP-834 and TP-271. Tetraphase Pharmaceuticals, Inc. is based in Watertown, Massachusetts.”
Insitutional Activity: The institutional sentiment decreased to 0.86 in Q2 2016. Its down 0.31, from 1.17 in 2016Q1. The ratio turned negative, as 18 funds sold all Tetraphase Pharmaceuticals Inc shares owned while 26 reduced positions. 14 funds bought stakes while 24 increased positions. They now own 21.31 million shares or 7.27% less from 22.99 million shares in 2016Q1.
Federated Invsts Inc Pa last reported 93,303 shares in the company. Rock Springs Capital Management L P has 425,000 shares for 0.14% of their US portfolio. California State Teachers Retirement Systems accumulated 76,320 shares or 0% of the stock. Renaissance Technology Lc has 784,805 shares for 0.01% of their US portfolio. The New York-based Joel Isaacson Ltd Liability Com has invested 0% in Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH). Morgan Stanley accumulated 24,279 shares or 0% of the stock. Vanguard Grp reported 1.29 million shares or 0% of all its holdings. Moreover, Wells Fargo & Mn has 0% invested in Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) for 14,402 shares. The California-based Dafna Capital Limited Liability has invested 0.35% in Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH). Manchester Mgmt Lc, a Vermont-based fund reported 7,492 shares. Canada Pension Plan Investment Board owns 1.98 million shares or 0.03% of their US portfolio. Loring Wolcott Coolidge Fiduciary Ltd Liability Partnership Ma, a Massachusetts-based fund reported 3,800 shares. Legal General Gru Public Ltd owns 6,756 shares or 0% of their US portfolio. Susquehanna Group Llp has invested 0% of its portfolio in Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH). Deutsche Natl Bank Ag reported 316,061 shares or 0% of all its holdings.
More notable recent Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) news were published by: Fool.com which released: “Why Tetraphase Pharmaceuticals Inc Stock Was Annihilated Today” on September 09, 2015, also Marketwatch.com with their article: “Tetraphase’s stock tumbles 21% to record low” published on April 15, 2013, Fool.com published: “Why Tetraphase Pharmaceuticals Dropped 74% of Its Value in 2015” on January 11, 2016. More interesting news about Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) were released by: Globenewswire.com and their article: “Tetraphase Pharmaceuticals Reports Second Quarter 2016 Financial Results and …” published on August 04, 2016 as well as Quotes.Wsj.com‘s news article titled: “News Tetraphase Pharmaceuticals Inc.TTPH” with publication date: March 22, 2013.
TTPH Company Profile
Tetraphase Pharmaceuticals, Inc. (Tetraphase), incorporated on July 7, 2006, is a clinical-stage biopharmaceutical company. The Firm uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Firm is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant Gram-negative infections. The Firm also develops TP-6076 for multidrug-resistant Gram- negative infections.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.